Canada. Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board (CPPIB)
Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced an investment commitment of up to US$20 million from Canada Pension Plan Investment Board (CPPIB). CPPIB joins Fusion’s existing group of top-tier investors adding to the US$105 million Series B announced in April 2019. The financing will primarily be used to expand the use of the Company’s Fast-Clear™ Linker Technology platform by investing in new partnerships and targeting molecules to create novel targeted alpha therapeutics, and...
